Literature DB >> 23679865

Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer.

Sebastien Taurin1, Hayley Nehoff, Jasper Diong, Lesley Larsen, Rhonda J Rosengren, Khaled Greish.   

Abstract

BACKGROUND: Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by its poor outcome and a lack of targeted therapies. Recently, our laboratory has developed a second generation curcumin derivative, 3,5-bis(3,4,5-trimethoxybenzylidene)-1-methylpiperidine-4-one (RL71) that shows potent in vitro cytotoxicity. RL71 is hydrophobic with poor bioavailability which limits its clinical development.
PURPOSE: We have designed styrene-co-maleic acid (SMA) micelles encapsulating 5, 10 or 15% RL71 by weight/weight ratio to improve its solubility and pharmacokinetic profile.
METHODS: The micelles charge, size and release rate were characterized. We evaluated their cytotoxicity against TNBC cell lines. The internalization of the drug inside the cells was measured by HPLC and the efficiency of the micelles was tested using a tumor spheroid model.
RESULTS: The micelles exhibited mean diameters of 125-185 nm and had a neutral charge. SMA-RL71 micelles have a cytotoxicity profile comparable to the free drug against several TNBC cell lines. Moreover, the 15% loaded micelles increased the stability of RL71 and demonstrated higher activity in a tumor spheroid model.
CONCLUSION: The current study demonstrates the efficiency of SMA for drug delivery, the influence of physicochemical characteristics on cytotoxicity, and provides the basis for preclinical testing in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23679865     DOI: 10.3109/1061186X.2013.796955

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  11 in total

1.  Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Authors:  Wenli Zhang; Guangji Wang; James R Falconer; Bruce C Baguley; John P Shaw; Jianping Liu; Hongtao Xu; Esther See; Jianguo Sun; Jiye Aa; Zimei Wu
Journal:  Pharm Res       Date:  2014-10-30       Impact factor: 4.200

Review 2.  Bringing Curcumin to the Clinic in Cancer Prevention: a Review of Strategies to Enhance Bioavailability and Efficacy.

Authors:  Rama I Mahran; Magda M Hagras; Duxin Sun; Dean E Brenner
Journal:  AAPS J       Date:  2016-10-25       Impact factor: 4.009

3.  Biodegradable micelles enhance the antiglioma activity of curcumin in vitro and in vivo.

Authors:  Songping Zheng; Xiang Gao; Xiaoxiao Liu; Ting Yu; Tianying Zheng; Yi Wang; Chao You
Journal:  Int J Nanomedicine       Date:  2016-06-09

4.  Triple Negative Breast Cancer: Nanosolutions for a Big Challenge.

Authors:  Tânia Filipa S Mendes; Leon D Kluskens; Lígia Raquel Rodrigues
Journal:  Adv Sci (Weinh)       Date:  2015-07-17       Impact factor: 16.806

5.  Folic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform.

Authors:  Xia Li; Myron R Szewczuk; Cecile Malardier-Jugroot
Journal:  Drug Des Devel Ther       Date:  2016-12-15       Impact factor: 4.162

6.  Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer.

Authors:  Orleans Martey; Mhairi Nimick; Sebastien Taurin; Vignesh Sundararajan; Khaled Greish; Rhonda J Rosengren
Journal:  Int J Nanomedicine       Date:  2017-10-04

7.  Targeted therapy of triple negative MDA-MB-468 breast cancer with curcumin delivered by epidermal growth factor-conjugated phospholipid nanoparticles.

Authors:  Kyung-Ho Jung; Jin Hee Lee; Jin Won Park; Da Hae Kim; Seung-Hwan Moon; Young Seok Cho; Kyung-Han Lee
Journal:  Oncol Lett       Date:  2018-04-12       Impact factor: 2.967

8.  PGMD/curcumin nanoparticles for the treatment of breast cancer.

Authors:  Mankamna Kumari; Nikita Sharma; Romila Manchanda; Nidhi Gupta; Asad Syed; Ali H Bahkali; Surendra Nimesh
Journal:  Sci Rep       Date:  2021-02-15       Impact factor: 4.379

Review 9.  The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers.

Authors:  Elizabeth Varghese; Samson Mathews Samuel; Mariam Abotaleb; Sohaila Cheema; Ravinder Mamtani; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2018-09-21       Impact factor: 6.639

Review 10.  Recent advances in nanotheranostics for triple negative breast cancer treatment.

Authors:  Vikram Thakur; Rajaletchumy Veloo Kutty
Journal:  J Exp Clin Cancer Res       Date:  2019-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.